At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Descovy 200Mg 25Mg Tablet +1 moredrug
Likely dose
Descovy 200Mg 25Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mobile Delivery of PrEP at a Syringe Services Program-A Pilot Study
In Brief
A Phase 4 clinical trial evaluating Descovy 200Mg 25Mg Tablet and PrEP for Hiv and Substance Use Disorders. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHiv, Substance Use Disorders
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartFeb 2022
Primary CompletionNov 2024
TodayJul 2026
First PostedMar 4, 2021
Enrollment StartFeb 1, 2022
Primary CompletionNov 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.3 years ago
Interventions
Descovy 200Mg 25Mg Tabletdrug
daily Descovy tab by mouth
PrEPbehavioral
PrEP will be provided in a community setting by community-based harm reduction program.